{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,12,24]],"date-time":"2022-12-24T05:58:03Z","timestamp":1671861483297},"reference-count":14,"publisher":"Hindawi Limited","issue":"6","license":[{"start":{"date-parts":[[2018,7,4]],"date-time":"2018-07-04T00:00:00Z","timestamp":1530662400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"},{"start":{"date-parts":[[2018,7,4]],"date-time":"2018-07-04T00:00:00Z","timestamp":1530662400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Clin Pharm Ther"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1111\/jcpt.12740","type":"journal-article","created":{"date-parts":[[2018,7,5]],"date-time":"2018-07-05T04:44:33Z","timestamp":1530765873000},"page":"914-917","source":"Crossref","is-referenced-by-count":0,"title":["Successful retreatment with lenalidomide for relapsed and refractory multiple myeloma previously treated with bortezomib, lenalidomide and pomalidomide"],"prefix":"10.1155","volume":"43","author":[{"given":"Satoko","family":"Oka","sequence":"first","affiliation":[{"name":"Division of Hematology; Japanese Red Cross Society Wakayama Medical Center; Wakayama Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuo","family":"Ono","sequence":"additional","affiliation":[{"name":"Division of Pathology; Japanese Red Cross Society Wakayama Medical Center; Wakayama Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaharu","family":"Nohgawa","sequence":"additional","affiliation":[{"name":"Division of Hematology; Japanese Red Cross Society Wakayama Medical Center; Wakayama Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"98","published-online":{"date-parts":[[2018,7,4]]},"reference":[{"key":"10.1111\/jcpt.12740-BIB0001|jcpt12740-cit-0001","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1056\/NEJMra1011442","article-title":"Multiple myeloma","volume":"364","author":"Palumbo","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1111\/jcpt.12740-BIB0002|jcpt12740-cit-0002","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1182\/blood-2012-01-405977","article-title":"Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides","volume":"120","author":"Egan","year":"2012","journal-title":"Blood"},{"key":"10.1111\/jcpt.12740-BIB0003|jcpt12740-cit-0003","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1200\/JCO.1994.12.11.2398","article-title":"Immunoglobulin D multiple myeloma: presenting features, response to therapy, and survival in a series of 53 cases","volume":"12","author":"Blade","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1111\/jcpt.12740-BIB0004|jcpt12740-cit-0004","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1046\/j.1365-2141.1996.5191061.x","article-title":"Presenting features and prognosis in 72 patients with multiple myeloma who were younger than 40 years","volume":"93","author":"Blade","year":"1996","journal-title":"Br J Haematol"},{"key":"10.1111\/jcpt.12740-BIB0005|jcpt12740-cit-0005","doi-asserted-by":"crossref","first-page":"SCI-5","DOI":"10.1182\/blood.V114.22.SCI-5.SCI-5","article-title":"Extramedullary Myeloma","volume":"114","author":"Blade","year":"2009","journal-title":"Blood"},{"issue":"30","key":"10.1111\/jcpt.12740-BIB0006|jcpt12740-cit-0006","doi-asserted-by":"crossref","first-page":"4621","DOI":"10.1200\/JCO.2009.27.9158","article-title":"Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial","volume":"28","author":"Harousseau","year":"2010","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1111\/jcpt.12740-BIB0007|jcpt12740-cit-0007","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1111\/jcpt.12740-BIB0008|jcpt12740-cit-0008","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1470-2045(09)70284-0","article-title":"Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial","volume":"11","author":"Rajkumar","year":"2010","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1111\/jcpt.12740-BIB0009|jcpt12740-cit-0009","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S1470-2045(13)70380-2","article-title":"Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial","volume":"14","author":"Miguel","year":"2013","journal-title":"Lancet Oncol"},{"issue":"21","key":"10.1111\/jcpt.12740-BIB0010|jcpt12740-cit-0010","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1182\/blood-2015-11-682518","article-title":"Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma","volume":"127","author":"Baz","year":"2016","journal-title":"Blood"},{"issue":"13","key":"10.1111\/jcpt.12740-BIB0011|jcpt12740-cit-0011","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1182\/blood-2016-06-723007","article-title":"Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma","volume":"128","author":"Weinhold","year":"2016","journal-title":"Blood"},{"key":"10.1111\/jcpt.12740-BIB0012|jcpt12740-cit-0012","unstructured":"National Comprehensive Cancer Network http:\/\/www.nccn.org\/professionals\/physician_gls\/PDF\/myeloma.pdf"},{"issue":"1","key":"10.1111\/jcpt.12740-BIB0013|jcpt12740-cit-0013","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/leu.2011.310","article-title":"Treatment strategies in relapsed and refractory multiple myeloma: a focus on drug sequencing and \u2018retreatment\u2019 approaches in the era of novel agents","volume":"26","author":"Mohty","year":"2012","journal-title":"Leukemia"},{"issue":"1","key":"10.1111\/jcpt.12740-BIB0014|jcpt12740-cit-0014","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s40265-017-0841-y","article-title":"Current and new therapeutic strategies for relapsed and refractory multiple myeloma: an update","volume":"78","author":"Nijhof","year":"2018","journal-title":"Drugs"}],"container-title":["Journal of Clinical Pharmacy and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjcpt.12740","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/jcpt.12740\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T18:03:50Z","timestamp":1671818630000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jcpt.12740"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,4]]},"references-count":14,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,12]]}},"URL":"https:\/\/doi.org\/10.1111\/jcpt.12740","archive":["Portico"],"relation":{},"ISSN":["0269-4727"],"issn-type":[{"value":"0269-4727","type":"print"}],"subject":[],"published":{"date-parts":[[2018,7,4]]}}}